Mangoceuticals Seeks Global Patent for MGX-0024 in Over 150 Countries after 29,000-Bird Trial
Mangoceuticals filed a PCT international application on February 26, 2026 extending patent protection for its MGX-0024 antiviral feed and drinking water additive to over 150 countries. The application builds on results showing zero respiratory mortality across 29,000 birds in field trials and significant prophylactic benefit against H5N1 in controlled studies.
1. PCT Application Filing
Mangoceuticals filed a Patent Cooperation Treaty application (P-641039-PC) on February 26, 2026 to secure international patent protection for MGX-0024, covering antiviral technology for animal feed and drinking water and streamlining patent pursuit across more than 150 countries.
2. Efficacy Data from Field Trials
The PCT filing builds on commercial field trials demonstrating zero respiratory-related mortality among 29,000 birds and results from an ICAR-NIHSAD controlled challenge study showing statistically significant prophylactic benefit against H5N1, reinforcing the additive's antiviral efficacy.
3. Global IP Strategy and Next Steps
The technology is already protected in the U.S. under Patent No. 11,517,523 with national patents granted or pending in the EU, Canada, China, India, Australia, and Japan, positioning the company to advance distributor agreements and regulatory submissions in key markets.